The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.
Tomonori Araki
No relevant relationships to disclose
Tetsuya Hamaguchi
No relevant relationships to disclose
Atsuo Takashima
No relevant relationships to disclose
Yoshitaka Honma
No relevant relationships to disclose
Satoru Iwasa
No relevant relationships to disclose
Natsuko T. Okita
No relevant relationships to disclose
Ken Kato
No relevant relationships to disclose
Yasuhide Yamada
No relevant relationships to disclose
Hironobu Hashimoto
No relevant relationships to disclose
Hirokazu Taniguchi
No relevant relationships to disclose
Ryoji Kushima
No relevant relationships to disclose
Kazuhiko Nakao
No relevant relationships to disclose
Yasuhiro Shimada
No relevant relationships to disclose